Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
Status:
Active, not recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is a study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics
(PD) and anti-tumor activity of DS-1001b in patients with gliomas that harbor IDH1-R132
mutations.